2Yachida S, Mudali S, Martin SA, et al. BetmCatenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol, 2009, 33: 1823-1832.
3Li I., Fu XS, Zhang W, et al. Wnt signaling pathway is activated in right colon serrated polyps correlating to specific molecular form of Ⅱ-catenin. Hum Pathol, 2013, 44: 1079- 1088.
4Kohonen-Corish M, Sigglekow N, Susanto J, et al. Promoter methylation of the mutated in eolorectal cancer gene is a frequent early event in coloreetal cancer. Oncogene, 2007, 26: 4435-4441.
5Kriegl L, Vieth M, Kirchner T, et al. Up-regulation of c-MYC and SIRT1 expression correlated with malignant transformation in the serrated route to colorectal cancer. Oncotarget, 2012, 3: 1182-1193.
6Fu X, Li J, Li K, et al. Hypermethylation of APC promoter 1A is associated with moderate activation of Wnt signaling pathway in a subset of colorectal serrated adenomas. Histopathology, 2009, 55: 554-563.
7Snover DC. Update on the serrated pathway to eoloreetal carcinoma. Hum Pathol, 2011, 42: 1-10.
8Kim KM, Lee EJ, Ha S, et al. Molecular features of colorectal hyperplastie polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol, 2011, 35: 1274-1286.
9Cunningham KS, Riddellv RH. Serrated mucosal lesions of the colorectum. Curr Opin Gastroenterol, 2006, 22: 48-53.
10Snover DC, Jass JR, Fenoglio-Preiser C, et al. Serrated polyps of the large intestine= a morphologic and molecular review of an evolving concept. Am J Clin Pathol, 2005, 124:380- 391.
二级参考文献25
1Telang N, Katdare M. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review). Oncol Rep, 2011, 25: 1195-1201.
2de Sousa EM, Vermeulen I., Richel D, et al. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res, 2011, 17:647 653.
3Greenspan F.J, Nichols FC, Rosenberg DW. Molecular alterations associated with sulindac resistant colon tumors in APCMin/+ mice. Cancer PrevRes (Phila), 2010, 3: 1187-1197.
4Reuter BK, Zhang XJ, Miller M.I. Therapeutic utility of aspirin in the APCMin/+ murine model of colon carcinogenesis. BMC Cancer, 2002, 2: 19.
5Jacoby RF, Seihert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celeeoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res, 2000, 60:5040 5044.
6Ritland SIR, Gendler SJ. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis, 1999, 20: 51- 58.
7Rao CV, Cooma I, Rodriguez JG, et al. Chemoprevention of familial adenomatous polyposis development in the ApcMin mouse model by 1,4 phenylene his(methylene) selenocyanate. Carcinogenesis, 2000, 21: 617-621.
8Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApeMin/+ mice. Cancer Sci, 2008, 99:2136 2141.
9Yamaguchi K, Cekanova M, McEntee MF, et al. Peroxisome proliferator-activated receptor ligand MCC 555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal- regulated kinase and peroxisome proliferator-aetivated receptor dependent pathways. Mol Cancer Ther, 2008, 7:2779- 2787.
10Swamy MV, Patlolla JM, Steele VE, et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMi- mice. Cancer Res, 2006, 66: 7370 7377.
